Literature DB >> 30998425

Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Thomas R O'Brien1, Howard A Young2, Raymond P Donnelly3, Ludmila Prokunina-Olsson4.   

Abstract

A meeting entitled, "Interferon Lambda: Disease Impact and Translational Potential," was held on the campus of the National Institutes of Health in Bethesda, Maryland, on October 25-26, 2018. To our knowledge, this was the first meeting that focused exclusively on interferon lambda (IFN-λ). The meeting's purpose was to enhance interdisciplinary communication and promote new collaborations. The gathering brought together an international group of scientists from a wide range of disciplines. Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ-Hepatic Fibrosis and Cancer. The next meeting on IFN-λ is planned for 2020.

Entities:  

Keywords:  cancer; genetics; hepatitis C virus; immunology; infectious diseases; interferon lambda

Mesh:

Substances:

Year:  2019        PMID: 30998425      PMCID: PMC6767859          DOI: 10.1089/jir.2019.0018

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  32 in total

1.  A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Authors:  Andrew J Muir; Sanjeev Arora; Gregory Everson; Robert Flisiak; Jacob George; Reem Ghalib; Stuart C Gordon; Todd Gray; Susan Greenbloom; Tarek Hassanein; Jan Hillson; Maria Arantxa Horga; Ira M Jacobson; Lennox Jeffers; Kris V Kowdley; Eric Lawitz; Stefan Lueth; Maribel Rodriguez-Torres; Vinod Rustgi; Lynn Shemanski; Mitchell L Shiffman; Subasree Srinivasan; Hugo E Vargas; John M Vierling; Dong Xu; Juan C Lopez-Talavera; Stefan Zeuzem
Journal:  J Hepatol       Date:  2014-07-24       Impact factor: 25.083

2.  Type III IFNs Are Commonly Induced by Bacteria-Sensing TLRs and Reinforce Epithelial Barriers during Infection.

Authors:  Charlotte Odendall; Andrew A Voak; Jonathan C Kagan
Journal:  J Immunol       Date:  2017-09-27       Impact factor: 5.422

3.  Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection.

Authors:  Megan T Baldridge; Timothy J Nice; Broc T McCune; Christine C Yokoyama; Amal Kambal; Michael Wheadon; Michael S Diamond; Yulia Ivanova; Maxim Artyomov; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

4.  License to kill: IFN-λ regulates antifungal activity of neutrophils.

Authors:  Daniel Schnepf; Peter Staeheli
Journal:  Sci Immunol       Date:  2017-11-17

5.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

6.  Race or genetic makeup for hepatitis C virus treatment decisions?

Authors:  Thomas R O'Brien; Shyam Kottilil; Jordan J Feld; Timothy R Morgan; Ruth M Pfeiffer
Journal:  Hepatology       Date:  2017-04-18       Impact factor: 17.425

Review 7.  Interferon-lambda: a new addition to an old family.

Authors:  Raymond P Donnelly; Sergei V Kotenko
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

8.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  IFNL4-ΔG is associated with prostate cancer among men at increased risk of sexually transmitted infections.

Authors:  Tsion Zewdu Minas; Wei Tang; Cheryl J Smith; Olusegun O Onabajo; Adeola Obajemu; Tiffany H Dorsey; Symone V Jordan; Obadi M Obadi; Bríd M Ryan; Ludmila Prokunina-Olsson; Christopher A Loffredo; Stefan Ambs
Journal:  Commun Biol       Date:  2018-11-14
View more
  1 in total

1.  Inhibition of SARS-CoV-2 by type I and type III interferons.

Authors:  Ulrike Felgenhauer; Andreas Schoen; Hans Henrik Gad; Rune Hartmann; Andreas R Schaubmar; Klaus Failing; Christian Drosten; Friedemann Weber
Journal:  J Biol Chem       Date:  2020-06-25       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.